You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNeostigmine
Accession NumberDB01400
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. [PubChem]
Structure
Thumb
Synonyms
(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate
3-Trimethylammoniumphenyl N,N-dimethylcarbamate
Eustigmin
Eustigmine
m-Trimethylammoniumphenyldimethylcarbamate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BloxiverzInjection1 mg/mLIntravenousEclat Pharmaceuticals, LLC2013-07-24Not applicableUs
BloxiverzInjection.5 mg/mLIntravenousEclat Pharmaceuticals, LLC2013-07-24Not applicableUs
BloxiverzInjection1 mg/mLIntravenousEclat Pharmaceuticals, LLC2013-07-24Not applicableUs
BloxiverzInjection.5 mg/mLIntravenousEclat Pharmaceuticals, LLC2013-07-24Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/mLIntravenousREMEDYREPACK INC.2015-10-26Not applicableUs
Neostigmine MethylsulfateInjection, solution.5 mg/mLIntravenousFresenius Kabi USA, LLC2015-01-08Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/mLIntravenousGeneral Injectables and Vaccines, Inc2016-08-11Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/mLIntravenousFresenius Kabi USA, LLC2015-01-08Not applicableUs
Neostigmine Methylsulfate Inj 0.5mg/ml USPLiquid.5 mgIntramuscular; Intravenous; SubcutaneousDavid Bull Laboratories (Pty) Ltd.1992-12-311996-09-10Canada
Neostigmine Methylsulfate Inj 1mg/ml USPLiquid1 mgIntramuscular; Intravenous; SubcutaneousDavid Bull Laboratories (Pty) Ltd.1991-12-311996-09-10Canada
Neostigmine Methylsulfate InjectionLiquid1 mgIntramuscular; Intravenous; SubcutaneousFresenius Kabi Canada LtdNot applicableNot applicableCanada
Neostigmine Methylsulfate InjectionLiquid0.5 mgIntramuscular; Intravenous; SubcutaneousFresenius Kabi Canada LtdNot applicableNot applicableCanada
Neostigmine Methylsulfate Injection SdzSolution0.5 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Neostigmine Methylsulfate Injection SdzSolution2.5 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Neostigmine Methylsulfate Injection USPSolution2.5 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1991-12-31Not applicableCanada
Neostigmine Methylsulfate Injection USPSolution0.5 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1990-12-31Not applicableCanada
Neostigmine Methylsulfate Injection USPLiquid1 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1990-12-31Not applicableCanada
Neostigmine OmegaLiquid1 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd1999-06-23Not applicableCanada
Neostigmine OmegaLiquid0.5 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd1999-05-28Not applicableCanada
Neostigmine OmegaSolution2.5 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2013-04-17Not applicableCanada
PMS-neostigmine Methylsulfate Inj 0.5mg/mlLiquid.5 mgIntramuscular; Intravenous; SubcutaneousPharmascience Inc1990-12-31Not applicableCanada
PMS-neostigmine Methylsulfate Inj 1mg/mlLiquid1 mgIntramuscular; Intravenous; SubcutaneousPharmascience Inc1990-12-31Not applicableCanada
Prostigmin Inj 1:1000 USPLiquid1 mgIntramuscular; Intravenous; SubcutaneousIcn Canada Ltd.1988-12-312005-04-26Canada
Prostigmin Inj 1:2000 USPLiquid.5 mgIntramuscular; Intravenous; SubcutaneousIcn Canada Ltd.1988-12-312005-04-26Canada
Prostigmin Inj 1:400 USPSolution2.5 mgIntramuscular; Intravenous; SubcutaneousIcn Canada Ltd.1988-12-312005-04-26Canada
Prostigmin TabletsTablet15 mgOralValeant Canada Lp/valeant Canada s.e.c.1988-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neostigmine MethylsulfateInjection1 mg/mLIntravenousWest Ward Pharmaceuticals Corp.2015-12-28Not applicableUs
Neostigmine MethylsulfateInjection.5 mg/mLIntravenousWest Ward Pharmaceuticals Corp.2015-12-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neostigmine MethylsulfateInjection, solution5 mg/mLIntramuscular; Intravenous; SubcutaneousFresenius Kabi USA, LLC2000-10-18Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousAmerican Regent, Inc.2003-01-162016-10-19Us
Neostigmine MethylsulfateInjection1 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1973-01-01Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousFresenius Kabi USA, LLC2000-09-01Not applicableUs
Neostigmine MethylsulfateInjection, solution.5 mg/mLIntramuscular; Intravenous; SubcutaneousAmerican Regent, Inc.2003-01-172016-10-19Us
Neostigmine MethylsulfateInjection.5 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1973-01-01Not applicableUs
Neostigmine MethylsulfateInjection.5 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1973-01-01Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/mLIntravenousCantrell Drug Company2015-02-03Not applicableUs
Neostigmine MethylsulfateInjection1 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1973-01-01Not applicableUs
International Brands
NameCompany
ProstigminNot Available
VagostigminNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Neostigmine bromide
114-80-7
Thumb
  • InChI Key: LULNWZDBKTWDGK-UHFFFAOYSA-M
  • Monoisotopic Mass: 302.062991
  • Average Mass: 303.2
DBSALT001191
Neostigmine methylsulfate
51-60-5
Thumb
  • InChI Key: OSZNNLWOYWAHSS-UHFFFAOYSA-M
  • Monoisotopic Mass: 334.119857136
  • Average Mass: 334.389
DBSALT000128
Categories
UNII3982TWQ96G
CAS number59-99-4
WeightAverage: 223.2915
Monoisotopic: 223.144652862
Chemical FormulaC12H19N2O2
InChI KeyALWKGYPQUAPLQC-UHFFFAOYSA-N
InChI
InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
IUPAC Name
3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium
SMILES
CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
Pharmacology
IndicationNeostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
Structured Indications
PharmacodynamicsNeostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction.
Mechanism of actionNeostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.
TargetKindPharmacological actionActionsOrganismUniProt ID
AcetylcholinesteraseProteinyes
inhibitor
HumanP22303 details
Related Articles
AbsorptionNeostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration
Volume of distributionNot Available
Protein bindingProtein binding to human serum albumin ranges from 15 to 25 percent.
Metabolism

Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver.

Route of eliminationNot Available
Half lifeThe half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.
ClearanceNot Available
ToxicityOverdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 ± 0.02 mg/kg intravenously, 0.54 ± 0.03 mg/kg subcutaneously, and 0.395 ± 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 ± 0.019 mg/kg intravenously, 0.445 ± 0.032 mg/kg subcutaneously, and 0.423 ± 0.032 mg/kg intramuscularly.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Neostigmine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Neostigmine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Neostigmine.Experimental, Illicit
AcebutololNeostigmine may increase the bradycardic activities of Acebutolol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Neostigmine.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Acetylcholine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Neostigmine.Approved, Vet Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Neostigmine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Neostigmine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Neostigmine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Neostigmine.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Neostigmine.Approved, Investigational
AlprenololNeostigmine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Neostigmine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Neostigmine.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Neostigmine.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Neostigmine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Neostigmine.Approved
Aop200704Neostigmine may increase the bradycardic activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Neostigmine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Arecoline.Experimental
ArotinololNeostigmine may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Neostigmine.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Neostigmine.Approved, Investigational
AtenololNeostigmine may increase the bradycardic activities of Atenolol.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Neostigmine.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Neostigmine.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Neostigmine.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Neostigmine.Approved, Investigational
BefunololNeostigmine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Neostigmine.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Neostigmine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Neostigmine.Approved, Vet Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Neostigmine.Approved, Vet Approved
BetaxololNeostigmine may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Neostigmine is combined with Bethanechol.Approved
BevantololNeostigmine may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Neostigmine.Approved
BisoprololNeostigmine may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Neostigmine.Approved
BopindololNeostigmine may increase the bradycardic activities of Bopindolol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Neostigmine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Neostigmine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Neostigmine.Approved, Investigational
BucindololNeostigmine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Neostigmine.Approved
BufuralolNeostigmine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololNeostigmine may increase the bradycardic activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Neostigmine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Neostigmine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Neostigmine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Neostigmine.Approved
CarbacholThe risk or severity of adverse effects can be increased when Neostigmine is combined with Carbachol.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Neostigmine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Neostigmine.Approved
CarteololNeostigmine may increase the bradycardic activities of Carteolol.Approved
CarvedilolNeostigmine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololNeostigmine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Neostigmine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Neostigmine.Withdrawn
CevimelineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Neostigmine.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Neostigmine.Approved, Vet Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Neostigmine.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Neostigmine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Neostigmine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Neostigmine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Neostigmine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Neostigmine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Neostigmine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Neostigmine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Neostigmine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Neostigmine.Approved
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Neostigmine.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Neostigmine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Neostigmine.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Neostigmine.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Neostigmine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Neostigmine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Neostigmine.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Neostigmine.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Neostigmine.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Neostigmine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Neostigmine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Neostigmine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Neostigmine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Neostigmine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Neostigmine.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Neostigmine.Approved, Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Neostigmine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Neostigmine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Neostigmine.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Neostigmine.Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Neostigmine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Neostigmine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Neostigmine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Neostigmine.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Neostigmine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Neostigmine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Neostigmine.Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Neostigmine.Approved, Illicit, Vet Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Neostigmine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Neostigmine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Neostigmine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Neostigmine.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Neostigmine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Neostigmine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Neostigmine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Neostigmine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Neostigmine.Approved
DipyridamoleThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Neostigmine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Neostigmine.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Neostigmine.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Neostigmine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Neostigmine.Approved, Investigational
EPIBATIDINEThe risk or severity of adverse effects can be increased when Neostigmine is combined with EPIBATIDINE.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Neostigmine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Neostigmine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Neostigmine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Neostigmine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Neostigmine.Approved, Vet Approved
EsmololNeostigmine may increase the bradycardic activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Neostigmine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Neostigmine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Neostigmine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Neostigmine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Neostigmine.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Neostigmine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Neostigmine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Neostigmine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Neostigmine.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Neostigmine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Neostigmine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Neostigmine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Neostigmine.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Neostigmine.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Neostigmine.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Neostigmine.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Neostigmine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Neostigmine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Neostigmine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Neostigmine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Neostigmine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Neostigmine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Neostigmine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Neostigmine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Neostigmine.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Neostigmine.Approved, Investigational, Withdrawn
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Neostigmine.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Neostigmine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Neostigmine.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Neostigmine.Approved, Investigational, Vet Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Neostigmine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Neostigmine.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Neostigmine is combined with GTS-21.Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Neostigmine.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Neostigmine.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Neostigmine.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Neostigmine.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Neostigmine.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Neostigmine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Neostigmine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Neostigmine.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Neostigmine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Neostigmine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Neostigmine.Approved
IndenololNeostigmine may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Neostigmine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Neostigmine.Approved, Investigational
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Neostigmine.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Neostigmine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Neostigmine.Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Neostigmine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Neostigmine.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Neostigmine.Approved, Investigational
LabetalolNeostigmine may increase the bradycardic activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Neostigmine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Neostigmine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Neostigmine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Neostigmine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Neostigmine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Neostigmine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Neostigmine.Approved, Investigational
LevobunololNeostigmine may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Neostigmine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Neostigmine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Neostigmine.Approved
LobelineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Lobeline.Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Neostigmine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Neostigmine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Neostigmine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Neostigmine.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Neostigmine.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Neostigmine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Neostigmine.Vet Approved
MethacholineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Methacholine.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Neostigmine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Neostigmine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Neostigmine.Approved, Vet Approved
MetipranololNeostigmine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Neostigmine.Approved
MetoprololNeostigmine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Neostigmine.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Neostigmine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Neostigmine.Approved, Investigational
MivacuriumNeostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Neostigmine.Approved, Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Neostigmine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Neostigmine.Approved, Investigational
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Neostigmine.Vet Approved
NadololNeostigmine may increase the bradycardic activities of Nadolol.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Neostigmine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Neostigmine.Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Neostigmine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Neostigmine.Approved
NicotineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Neostigmine is combined with Nicotine bitartrate.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Neostigmine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Neostigmine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Neostigmine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Neostigmine.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Neostigmine.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Neostigmine.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Neostigmine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Neostigmine.Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Neostigmine.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Neostigmine.Approved
OxprenololNeostigmine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Neostigmine.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Neostigmine.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Neostigmine.Approved, Vet Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Neostigmine.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Neostigmine.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Neostigmine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Neostigmine.Approved
PenbutololNeostigmine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Neostigmine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Neostigmine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Neostigmine.Approved, Vet Approved
PilocarpineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Pilocarpine.Approved
PindololNeostigmine may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Neostigmine.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Neostigmine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Neostigmine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Neostigmine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Neostigmine.Approved
PractololNeostigmine may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Neostigmine.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Neostigmine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Neostigmine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Neostigmine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Neostigmine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Neostigmine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Neostigmine.Experimental
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Neostigmine.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Neostigmine.Approved, Vet Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Neostigmine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Neostigmine.Investigational
PropranololNeostigmine may increase the bradycardic activities of Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Neostigmine.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Neostigmine.Approved
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Neostigmine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Neostigmine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Neostigmine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Neostigmine.Approved, Investigational
RapacuroniumNeostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Neostigmine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Neostigmine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Neostigmine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Neostigmine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Neostigmine.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Neostigmine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Neostigmine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Neostigmine.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Neostigmine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Neostigmine.Approved, Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Neostigmine.Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Neostigmine.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Neostigmine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Neostigmine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Neostigmine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Neostigmine.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Neostigmine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Neostigmine.Approved, Investigational
SotalolNeostigmine may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Neostigmine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Neostigmine.Experimental
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Neostigmine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Neostigmine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Neostigmine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Neostigmine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Neostigmine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Neostigmine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Neostigmine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Neostigmine.Approved
TimololNeostigmine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Neostigmine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Neostigmine.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Neostigmine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Neostigmine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Neostigmine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Neostigmine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Neostigmine.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Neostigmine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Neostigmine.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Neostigmine.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Neostigmine.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Neostigmine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Neostigmine.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Neostigmine.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Neostigmine.Approved
VareniclineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Neostigmine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Neostigmine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Neostigmine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Neostigmine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Neostigmine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Neostigmine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Neostigmine.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Neostigmine.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN07AA51S01EB06N07AA01
AHFS Codes
  • 12:04.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8576
Blood Brain Barrier+0.9583
Caco-2 permeable+0.608
P-glycoprotein substrateNon-substrate0.8263
P-glycoprotein inhibitor INon-inhibitor0.9598
P-glycoprotein inhibitor IINon-inhibitor0.9279
Renal organic cation transporterNon-inhibitor0.9181
CYP450 2C9 substrateNon-substrate0.7197
CYP450 2D6 substrateNon-substrate0.6869
CYP450 3A4 substrateSubstrate0.622
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9367
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9424
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8362
Ames testAMES toxic0.5146
CarcinogenicityNon-carcinogens0.5931
BiodegradationNot ready biodegradable0.7893
Rat acute toxicity2.9481 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.8738
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous; Subcutaneous.5 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous1 mg/mL
InjectionIntravenous.5 mg/mL
InjectionIntravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous.5 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous1 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous5 mg/mL
Injection, solutionIntravenous.5 mg/mL
Injection, solutionIntravenous1 mg/mL
SolutionIntramuscular; Intravenous; Subcutaneous0.5 mg
SolutionIntramuscular; Intravenous; Subcutaneous2.5 mg
LiquidIntramuscular; Intravenous; Subcutaneous0.5 mg
LiquidIntramuscular; Intravenous; Subcutaneous.5 mg
LiquidIntramuscular; Intravenous; Subcutaneous1 mg
TabletOral15 mg
Prices
Unit descriptionCostUnit
Neostigmine bromide powder96.57USD g
Neostigmine ms 5 mg/5 ml syr1.99USD ml
Prostigmin 1:4000 ampul1.42USD ml
Prostigmin 15 mg tablet1.04USD tablet
Neostigmine 1:1000 vial0.48USD ml
Neostigmine 1:2000 vial0.48USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0677 mg/mLALOGPS
logP-1.6ALOGPS
logP-2.2ChemAxon
logS-3.6ALOGPS
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity75.28 m3·mol-1ChemAxon
Polarizability25.08 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as substituted anilines. These are organic compound containing an aniline group substituted at one or more positions.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilines
Direct ParentSubstituted anilines
Alternative Parents
Substituents
  • Substituted aniline
  • Tertiary amine
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic cation
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Trevisani GT, Hyman NH, Church JM: Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000 May;43(5):599-603. [PubMed:10826417 ]
  2. Naves LA, Van der Kloot W: Repetitive nerve stimulation decreases the acetylcholine content of quanta at the frog neuromuscular junction. J Physiol. 2001 May 1;532(Pt 3):637-47. [PubMed:11313435 ]
  3. Takeuchi K, Kawauchi S, Araki H, Ueki S, Furukawa O: Stimulation by nizatidine, a histamine H(2)-receptor antagonist, of duodenal HCO(3)(-)secretion in rats:relation to anti-cholinesterase activity. World J Gastroenterol. 2000 Oct;6(5):651-658. [PubMed:11819669 ]
  4. Minic J, Chatonnet A, Krejci E, Molgo J: Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions. Br J Pharmacol. 2003 Jan;138(1):177-87. [PubMed:12522088 ]
  5. Beck KD, Brennan FX, Moldow RL, Ottenweller JE, Zhu G, Servatius RJ: Stress interacts with peripheral cholinesterase inhibitors to cause central nervous system effects. Life Sci. 2003 May 23;73(1):41-51. [PubMed:12726885 ]
  6. Zhang B, Hepner DL, Tran MH, Friedman M, Korn JR, Menzin J: Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50. doi: 10.1185/03007990902769054 . [PubMed:19257799 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Saito S: Cholinesterase inhibitors induce growth cone collapse and inhibit neurite extension in primary cultured chick neurons. Neurotoxicol Teratol. 1998 Jul-Aug;20(4):411-9. [PubMed:9697967 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:06 / Updated on December 08, 2016 11:46